Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
12 September 2024 - 6:05AM
Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today
announced that David-Alexandre C. Gros, M.D., Chief Executive
Officer, will participate in a fireside chat at the upcoming Cantor
Global Healthcare Conference on Wednesday, September 18, 2024, at
8:35 a.m. ET.
To register in advance for the fireside chat webcast, sign up
here.
A webcast replay will be accessible following the live session
on the Company’s website under Events.
About Eledon Pharmaceuticals and
tegoprubart
Eledon Pharmaceuticals, Inc. is a clinical stage
biotechnology company that is developing immune-modulating
therapies for the management and treatment of life-threatening
conditions. The Company’s lead investigational product is
tegoprubart, an anti-CD40L antibody with high affinity for the CD40
Ligand, a well-validated biological target that has broad
therapeutic potential. The central role of CD40L signaling
in both adaptive and innate immune cell activation and
function positions it as an attractive target for
non-lymphocyte depleting, immunomodulatory therapeutic
intervention. The Company is building upon a deep historical
knowledge of anti-CD40 Ligand biology to conduct preclinical and
clinical studies in kidney allograft transplantation,
xenotransplantation, and amyotrophic lateral sclerosis (ALS).
Eledon is headquartered in Irvine, California. For
more information, please visit the Company’s website
at www.eledon.com.
Follow Eledon Pharmaceuticals on social
media: LinkedIn; Twitter
Investor Contact:
Stephen JasperGilmartin Group(858) 525
2047stephen@gilmartinir.com
Media Contact:
Jenna UrbanBerry & Company Public Relations(212) 253
8881jurban@berrypr.com
Source: Eledon Pharmaceuticals
Eledon Pharmaceuticals (NASDAQ:ELDN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Eledon Pharmaceuticals (NASDAQ:ELDN)
Historical Stock Chart
From Oct 2023 to Oct 2024